Global health leaders, researchers, funders, and advocates convened in Geneva for a technical summit hosted by the World Health Organization (WHO). The gathering aimed to review progress in accelerating the development and equitable access to new tuberculosis (TB) vaccines for adults and adolescents.
TB remains a leading infectious killer, causing over 10 million illnesses and more than 1 million deaths annually.
Progress in Vaccine Development
Several promising TB vaccine candidates are currently in clinical trials. Optimism is high that new vaccines could significantly reduce TB-related illness and deaths, with some candidates expected to deliver critical efficacy results within the next two years.
Strengthening Collaboration and Preparedness
The summit marked the first joint session of the TB Vaccine Accelerator working groups. The primary goal was to align stakeholders and address existing gaps in the development pipeline. To support these efforts, an online platform was launched to facilitate knowledge-sharing, decision-making, and community engagement for future vaccine introduction. A key focus of these preparations is ensuring readiness for timely and equitable vaccine deployment in high-burden countries.
Navigating Regulatory and Policy Pathways
Experts examined the scientific, regulatory, and operational challenges of moving from clinical trials to concrete policy recommendations. A major highlight was the need to generate robust evidence to guide both global and country-level decisions on vaccine adoption.
Advancing Financing and Equity
Stakeholders are actively advancing innovative financing mechanisms and market-shaping strategies to support vaccine rollouts. Efforts are underway to expand regional vaccine manufacturing capacity and improve economic data, all with the ultimate goal of ensuring equitable access for everyone who needs it.